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Hepatitis B virus (HBV) infection constitutes a serious global health problem. Nowadays there are 
divergent data regarding the use of antiviral drugs to treat acute hepatitis B. We present here a 
case of a 62-year-old man affected by severe acute hepatitis
and  hepatic  function.  The  patient  was  treated  with  entecavir  without  critical  side  effects.  We 
observed rapid clinical and laboratory improvements and the disappearance of hepatitis B surface 
antigen (HBsAg). The treatment with entecavir was protracted until 17
anti-HBs  appeared.  Entecavir  should  be  carefully  considered for  the treatment  of  severe  acute 
hepatitis B cases.
Introduction: Acute hepatitis B viral (HBV) infection 
can sometimes take a severe course, leading to liver 
failure  due  to  hepatic  necrosis  with  a  death  rate  of 
80%.
1-2 Emergency  liver  transplantation  is  often  the 
only  therapeutic  option  available.
3 There  are  many 
drugs approved for the treatment of chronic hepatitis B, 
that  inhibit  the  replication  of  the  HBV  with  a  low 
toxicity and a good resistance profile such lamivudine, 
adefovir, tenofovir, entecavir and telbivudine.  Given 
their  safety,  these  drugs  may  represent  a  reasonable 
therapeutic option also in severe acute hepatitis B.
The new guidelines endorsed by America Association 
for the study of liver diseases (AASLD) recommend to 
treat  symptomatic  acute hepatitis in  patients 
with fulminant hepatitis and by severe acute hepatitis B 
and  suggesting  the  use  of  lamivudine  or  telbivudine 
when  the  anticipated  duration  of  treatment  is  short; 
otherwise, entecavir is preferred.
7
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old man affected by severe acute hepatitis B with progressive worsening of clinical 
and  hepatic  function.  The  patient  was  treated  with  entecavir  without  critical  side  effects.  We 
observed rapid clinical and laboratory improvements and the disappearance of hepatitis B surface 
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Acute hepatitis B viral (HBV) infection 
can sometimes take a severe course, leading to liver 
failure  due  to  hepatic  necrosis  with  a  death  rate  of 
Emergency  liver  transplantation  is  often  the 
There  are  many 
drugs approved for the treatment of chronic hepatitis B, 
that  inhibit  the  replication  of  the  HBV  with  a  low 
toxicity and a good resistance profile such lamivudine, 
adefovir, tenofovir, entecavir and telbivudine.  Given 
ir  safety,  these  drugs  may  represent  a  reasonable 
therapeutic option also in severe acute hepatitis B.
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The new guidelines endorsed by America Association 
for the study of liver diseases (AASLD) recommend to 
treat  symptomatic  acute hepatitis in  patients affected 
with fulminant hepatitis and by severe acute hepatitis B 
and  suggesting  the  use  of  lamivudine  or  telbivudine 
when  the  anticipated  duration  of  treatment  is  short; 
Patients are considered to have severe acute vira
hepatitis  B  if  they  fulfill  2  of  3  criteria:  (1)  hepatic 
encephalopathy;  (2)  serum  bilirubin  level  > 
10.0mg/dL;  and  (3)  international  normalized  ratio 
(INR) >1.6.
7-9
Case Report: A 62-year-old Italian man was admitted 
to the hospital because of jaundice, fever, fatigue, loss 
of appetite and dark urine. His history was negative for 
any  major  illness,  nor  alcohol  or  drugs  abuse.  He 
referred unprotect sexual contact two months before. 
At hospital admission the examination showed a frank 
jaundice  and  hepatomegaly.  No  splenomegaly,  nor 
flapping tremor, nor sleep or digestive disorders were 
observed.  The  laboratory  exams  showed  alanine 
aminotransferase  (ALT)  2304  mU/mL,  aspartate 
aminotransferase (AST) 1595mU/mL, gamma glutamil 
trans  peptidase    (γGT)  389  mU/mL,  direct  bilirubin 
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level  6.64  mg/dL,  total  bilirubin  level  9.53  mg/dL, 
prothrombin time activity percentage (PT) 64%, INR 
1.30, Glycaemia level 98mg/dL, ammonia 88 mg/dL, 
total  cholesterol  117  mg/dL,  HDL-cholesterol  13 
mg/dL. Hepatitis B markers were hepatitis B  surface 
antigen  (HBsAg)  positive,  quantitative  HBsAg 
>250.00 UI/ml,  antibodies anti surface  antigen  (anti-
HBs) were negative, antibodies to e antigen (anti-HBe) 
and  antibodies  to  core  antigen  (anti-HBc)  IgM  both 
positive, IgM index (sample/cut-off ratio) 25.98, HBV 
DNA 534258 UI/mL. The other hepatitis virus markers 
(HAV, HCV, HDV, EBV, CMV) were all negative for 
acute infection. His serologic  test was diagnostic for 
acute  hepatitis  B  and  the  diagnosis  was  strongly 
supported by the finding of high IgM core index.
10 To 
correct  the  INR  we  administered  10  mg  per  day  of 
phytomenadione for three days without improvement. 
The  patient  showed  a  progressive  worsening  of  the 
clinical conditions with slight mental confusion, sleep-
wake  rhythm  alteration,  reduction  of  alertness, 
anorexia, fever, marked asthenia, jaundice worsening, 
spleen enlargement (one cm from the costal arch) and 
increasing hepatomegaly.
The  laboratory  examination  showed  a  worsening 
condition:  INR  1.49,  ammonia  105  mg/dL,  total 
cholesterol 94 mg/dL, HDL cholesterol 12 mg/dL AST 
2237 mU/mL, ALT 3034 mU/mL, total bilirubin level 
19.36  mg/dL.  Electroencephalogram  (EEG)  showed 
anomalies  of  the  background  activities,  while  the 
abdominal  echography  confirmed  the  presence  of 
hepato-splenomegaly and marked the presence of small 
ascitic fluid that wasn’t detected when the patient was 
hospitalized.
At this stage, the patient presented criteria of severe 
acute hepatitis B, thus together with general supportive 
therapies as glucose solutions iv and lactulose solutions 
po,  we started  “off label“ treatment with entecavir 1 
mg daily. The patient was informed that the drug was 
not  approved  for  this  indication  and  he  gave  the 
consent for the treatment.  After three days of antiviral 
treatment the patient was stably apiretic, while after ten 
days  anorexia,  mental  confusion,  sleep-wake  rhythm 
alteration,  asthenia  disappeared,  jaundice  and 
hepatomegaly were reduced. Ten days after the start of 
entecavir  treatment,  the  laboratory  exams  confirmed 
the  improvement  of  hepatic  function:  INR  1.21, 
ammonia 79 mg/dL, total cholesterol level 159 mg/dL, 
AST  72  mU/mL,  ALT  261  mU/mL,  total  bilirubin 
level  13.29  mg/dL  (Figure  1).  Hepatitis  markers 
revealed:  HBsAg  and  quantitative  HBsAg  both 
negative and HBV DNA 65 UI/mL (Figure 1).
The patient was discharged after 15 days from the 
beginning of the antiviral treatment. At follow-up after 
three weeks from starting entecavir, ascitic effusions 
disappeared,  the  liver  and  spleen  dimension  and 
coagulation parameters were all normalized. Therapy 
was continued with entecavir 1 mg day for five weeks, 
the  dosage  was  decreased  to  0.5  mg  as  the  patient 
experienced a growth of hair loss. HBV DNA wasn’t 
detected after six weeks (figure 1). We continued the 
treatment with entecavir until the 17th week, when the 
anti-HBs appeared (15 UI/mL).
Discussion:  We  observed  rapid  improvement  of  a 
severe  acute  hepatitis  B  treated  with  entecavir,  in 
accordance  with  previous  reports.
3,6,11 In  medical 
literature there are divergent data regarding the use of 
antiviral  drugs  to  treat  acute  severe  hepatitis  B.  For 
instance,  lamivudine  has  proved  no  better  than 
placebo,
8 while others showed a reduction of mortality 
rate.
4,6 Theoretically lamivudine or telbivudine would 
be a reasonable choice given their safety and rapidity 
of action. Unfortunately HBV-resistance to lamivudine 
is increasingly reported. Monotherapy with entecavir, a 
new generation drug, showed encouraging preliminary 
results  in  patients  affected  by  acute  severe  hepatitis 
B.
3,6,11 Furthermore  clinical  trials  of  long-term 
entecavir treatment of chronic hepatitis B have shown a 
very low rate of resistance to this drug compared with 
other antiviral. So in severe acute hepatitis B, this drug 
seems to be a good reasonable choice when resistance 
profile is high or the patient could be considered at risk 
of infection by resistant virus.
7 Tenofovir and adefovir 
may  not  be  optimal  because  of  their  potential  for 
nephrotoxicity.
7 We  didn’t  know  the  patient’s  viral 
HBV resistance profile, so for safety and according to 
Jochum et al
11 we used entecavir at the dose of 1 mg 
for day considering the approved dose for lamivudine 
resistant patients.
7
The main concerns about the use of anti-HBV drugs 
during  the  acute  phase  are  principally  linked  to  two 
factors:  first,  the  antiviral  therapy  is  generally  not 
necessary because more than 95% of acute infections 
solve  spontaneously.
7 Second,  early  antiviral  therapy 
theoretically may inhibit the production of neutralizing 
antibody in the early phase of the disease and delays 
the  appearance  of  anti-HBs.  In  a  recent  study 
lamivudine used in acute hepatitis B has been reported 
to  determine  a  reduced  anti-HBs  seroconversion  as 
compared to patients not receiving the antiviral,
4 even 
if other studies did not observe significant differences.
8
Usually anti-HBs appear after one - two months from 
HBsAg disappearance, although in some patients not 
being treated with antiviral drugs, antibodies could not 
appear in weeks or even months.
12 In the reported case, 
antibodies anti-HBs appeared after about four monthsMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 1. Biochemical and viral parameters at admission and subsequent controls. Alanine aminotransferase (ALT) UI/mL, prothrombin 
time activity percentage (PT), hepatitis B antigen (HBsAg) UI/mL, antibody antiHBs (anti HBs), Hepatitis B DNA (HBV-DNA) UI/mL.
from the disappearance of the HBsAg. The duration of 
antiviral  treatment  is  not  established;  we  stopped 
entecavir at seroconversion to anti-HBs. However, this 
issue  is  still  controversial:  EASL  guidelines 
recommend  therapy  to  be  continued  for  at  least  3 
months  after  anti-HBs  appearance,
13 while  AASLD 
ones  until  HBsAg  clearance  is  confirmed.
7 Further 
studies  are  necessary  to  support  the  appropriateness 
and  the  duration  of  entecavir  treatment  in  cases  of 
acute severe hepatitis B. Meanwhile the possible use of 
this  drug  should  be  considered  for  selected  patients 
with acute hepatitis B.
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